Recent CVM News
- CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules • Business Wire • 07/11/2025 04:16:00 PM
- CEL-SCI Shares Jump on Strategic Saudi Deal for Cancer Immunotherapy Multikine • IH Market News • 07/11/2025 03:05:51 PM
- CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer • Business Wire • 07/11/2025 01:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/03/2025 08:09:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2025 01:29:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2025 01:26:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2025 01:22:49 PM
- FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients • Business Wire • 06/18/2025 01:00:00 PM
- CEL-SCI Announces Closing of Public Offering • Business Wire • 05/23/2025 08:05:00 PM
- CEL-SCI Announces Pricing of Public Offering • Business Wire • 05/22/2025 12:14:00 AM
- CEL-SCI Announces Proposed Public Offering • Business Wire • 05/21/2025 08:05:00 PM
- CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia • Business Wire • 05/21/2025 12:00:00 PM
- CEL-SCI Announces Combination of Common Stock • Business Wire • 05/19/2025 06:40:00 PM
- CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results • Business Wire • 05/15/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:20:57 PM
- CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market • Business Wire • 04/23/2025 12:30:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (US) • 04/14/2025 02:15:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (US) • 04/14/2025 02:10:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (Canada) • 04/14/2025 02:10:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/09/2025 05:00:21 PM
- New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses • Business Wire • 04/08/2025 01:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 01:51:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 01:49:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 01:46:47 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM